Lipopolysaccharide-binding and neutralizing activities of surfactin C in experimental models of septic shock

European Journal of Pharmacology

Volumn 556, Issue 1-3, 2007, Pages 166-171

  Hwang, Youn Hwan ^a   Park, Byung Kwon ^a   Lim, Jong Hwan ^b   Kim, Myoung Seok ^a   Park, Seung Chun ^c   Hwang, Mi Hyun ^c   Yun, Hyo In ^a  

^a Chungnam National University   (South Korea)

^b B and C Biopharm   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Lipopolysaccharide (LPS); Septic shock; Surfactin C

Indexed keywords

CHROMOGENIC SUBSTRATE; ENDOTOXIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE; POLYMYXIN B; SODIUM CHLORIDE; SURFACTIN; SURFACTIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; IN VITRO STUDY; INOCULATION; INSTITUTE FOR CANCER RESEARCH MOUSE; LIMULUS LYSATE TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; SEPTIC SHOCK; SPRAGUE DAWLEY RAT; SURVIVAL;

ANIMALS; ENDOTOXINS; ESCHERICHIA COLI; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE; PEPTIDES, CYCLIC; POLYMYXIN B; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846042565     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.031     Document Type: Article

References (42)

1. Arima K., Tsukagoshi N., and Tamura G. Inhibition of the synthesis of the alkaline phosphatase of Bacillus megaterium KM by a novel protoplast-bursting factor obtained from Bacillus subtilis 202-7. Biochim. Biophys. Acta, Biomembr. (1968) 117-120
2. Baumgart F., Kluge B., Ullrich C., Vater J., and Ziessow D. Identification of amino acid substitutions in the lipopeptide surfactin using 2D NMR spectroscopy. Biochem. Biophys. Res. Commun. 177 (1991) 998-1005
3. Bonmatin J.M., Genest M., Labbe H., and Ptak M. Solution three-dimensional structure of surfactin: a cyclic lipopeptide studied by 1H-NMR, distance geometry, and molecular dynamics. Biopolymers 34 (1994) 975-986
4. Brackett D.J., Lerner M.R., Lacquement M.A., He R., and Pereira H.A. A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infect. Immun. 65 (1997) 2803-2811
5. Campanile F., Giampietri A., Grohmann U., Belladonna M.L., Fioretti M.C., and Puccetti P. Evidence for tumor necrosis factor α as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis. Eur. J. Pharmacol. 307 (1996) 191-199
6. Camussi G., Mariano F., Biancone L., De Martino A., Bussolati B., Montrucchio G., and Tobias P.S. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. J. Immunol. 155 (1995) 316-324
7. Cirioni O., Giacometti A., Ghiselli R., Mocchegiani F., Fineo A., Orlando F., Rocchi M., Saba V., and Scalise G. Single-dose intraperitoneal magainins improve survival in a gram-negative-pathogen septic shock rat model. Antimicrob. Agents Chemother. 46 (2002) 101-104
8. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
9. David S.A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 14 (2001) 370-387
10. Desai J.D., and Banat I.M. Microbial production of surfactants and their commercial potential. Microbiol. Mol. Biol. Rev. 61 (1997) 47-64
11. Ghiselli R., Giacometti A., Cirioni O., Circo R., Mocchegiani F., Skerlavaj B., D'Amato G., Scalise G., Zanetti M., and Saba V. Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide. Shock 19 (2003) 577-581
12. Hwang M.H., Lim J.H., Yun H.I., Rhee M.H., Cho J.Y., Hsu W.H., and Park S.C. Surfactin C inhibits the lipopolysaccharide-induced transcription of interleukin-1beta and inducible nitric oxide synthase and nitric oxide production in murine RAW 264.7 cells. Biotechnol. Lett. 27 (2005) 1605-1608
13. Hue N., Serani L., and Laprevote O. Structural investigation of cyclic peptidolipids from Bacillus subtilis by high-energy tandem mass spectrometry. Rapid Commun. Mass Spectrom. 15 (2001) 203-209
14. Iskit A.B., and Guc M.O. A new therapeutic approach for the treatment of sepsis. Med. Hypotheses 62 (2004) 342-345
15. Jiang Z., Hong Z., Guo W., Xiaoyun G., Gengfa L., Yongning L., and Guangxia X. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int. Immunopharmacol. 4 (2004) 527-537
16. Kameda Y., Oira S., Matsui K., and Kanatomo S. Antitumor activity of Bacillus natto. V. Isolation and characterization of surfactin in the culture medium of Bacillus natto KMD 2311. Chem. Pharm. Bull. 22 (1974) 938-944
17. Khownium K., Wood S.J., Miller K.A., Balakrishna R., Nguyen T.B., Kimbrell M.R., Georg G.I., and David S.A. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds. Bioorg. Med. Chem. Lett. 16 (2006) 1305-1308
18. Kilbourn R.G., Jubran A., Gross S.S., Griffith O.W., Levi R., Adams J., and Lodato R.F. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem. Biophys. Res. Commun. 172 (1990) 1132-1138
19. Kikuchi T., and Hasumi K. Enhancement of plasminogen activation by surfactin C: augmentation of fibrinolysis in vitro and in vivo. Biochim. Biophys. Acta 1596 (2002) 234-245
20. Kim K., Jung S.Y., Lee D.K., Jung J.K., Park J.K., Kim D.K., and Lee C.H. Suppression of inflammatory responses by surfactin, a selective inhibitor of platelet cytosolic phospholipase A2. Biochem. Pharmacol. 55 (1998) 975-985
21. Knotek M., Rogachev B., Wang W., Ecder T., Melnikov V., Gengaro P.E., Esson M., Edelstein C.L., Dinarello C.A., and Schrier R.W. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int. 59 (2001) 2243-2249
22. Kowall M., Vater J., Kluge B., Stein T., Franke P., and Ziessow D. Separation and characterization of surfactin isoforms produced by Bacillus subtilis OKB 105. J. Colloid Interface Sci. 204 (1998) 1-8
23. Lim J.H., Kim M.S., Park B.K., Hwang Y.H., Hwang M.H., Park S.C., and Yun H.I. Systemic availability and pharmacokinetics of surfactin, a lipopeptide produced by Bacillus subtilis BC1212 in rats. J. Toxicol. Public Health 21 (2005) 319-323
24. Lindesmith L.A., Baines D.R., Bigelow D.B., and Petty T.L. Reversible respiratory paralysis associated with polymyxin therapy. Ann. Intern. Med. 68 (1967) 318-327
25. Llesuy S., Evelson P., Gonzalez-Flecha B., Peralta J., Carreras M.C., Poderoso J.J., and Boveris A. Oxidative stress in muscle and liver of rats with septic syndrome. Free Radic. Biol. Med. 16 (1994) 445-451
26. Mancuso G., Cusumano V., Cook J.A., Smith E., Squadrito F., Blandino G., and Teti G. Efficacy of tumor necrosis factor alpha and eicosanoid inhibitors in experimental models of neonatal sepsis. FEMS Immunol. Med. Microbiol. 9 (1994) 49-54
27. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I., and Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7 (2003) 78-83
28. Marschke G., and Sarauw A. Danger of polymyxin B inhalation. Ann. Intern. Med. 74 (1971) 296-297
29. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., Cerami A., Wolff S.M., and Wilmore D.W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318 (1988) 1481-1486
30. Nathan C., and Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 78 (1994) 915-918
31. Peypoux F., Bonmatin J.M., and Wallach J. Recent trends in the biochemistry of surfactin. Appl. Microbiol. Biotechnol. 51 (1999) 553-563
32. Pittet J.F., Morel D.F., Hemsen A., Gunning K., Lacroix J.S., Suter P.M., and Lundberg J.M. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 213 (1991) 261-264
33. Preiser J.C., Zhang H., Vray B., Hrabak A., and Vincent J.L. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogs. Nitric Oxide 5 (2001) 208-211
34. Sessler C.N., Bloomfield G.L., and Fowler A.A. Current concepts of sepsis and acute lung injury. Clin. Chest Med. 17 (1996) 213-235
35. Tsukagoshi N., Tamura G., and Arima K. A novel protoplast-bursting factor (surfactin) obtained from Bacillus subtilis IAM 1213. II. The interaction of surfactin with bacterial membranes and lipids. Biochim. Biophys. Acta 196 (1970) 211-214
36. Vasilev D., Karadimov D., Vogt J., and Santak B. Nitric oxide-a basic mediator of vasodilation and septic shock. Khirurgiia 49 (1996) 14-16
37. Vollenbroich D., Ozel M., Vater J., Kamp R.M., and Pauli G. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals 25 (1997) 289-297
38. Warren H.S., Kania S.A., and Siber G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob. Agents Chemother. 28 (1985) 107-112
39. Wood S.J., Miller K.A., and David S.A. Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents. Comb. Chem. High Throughput Screen. 7 (2004) 239-249
40. Wu C.C., Chen S.J., and Yen M.H. Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats. Am. J. Physiol. 275 (1998) 1148-1157
41. Wu C.C., Liao M.H., Chen S.J., and Yen M.H. Tetramethylpyradizine prevents inducible NO synthase expression and improves survival in rodent models of endotoxic shock. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 435-444
42. Zanetti M., Gennaro R., Skerlavaj B., Tomasinsig L., and Circo R. Cathelicidin peptides as candidates for a novel class of antimicrobials. Curr. Pharm. Des. 8 (2002) 779-793